Navigation Links
KaloBios to Present KB004 Interim Phase 1 Clinical Data in Hematologic Malignancies at ASH
Date:11/7/2013

s for the CF indication and has initiated a 180 patient Phase 2 study in CF subjects with chronic Pa lung infection in the United States. KaloBios has received Orphan Drug designation from both the FDA and the European Commission for KB001-A for the treatment of CF patients with Pa lung infection. Sanofi is pursuing a ventilator-associated pneumonia prevention indication in the intensive care setting, an indication which has received U.S. FDA Fast Track Designation.
  • KB004, an anti-EphA3 mAb, has potential in treating hematologic malignancies and solid tumors. KaloBios is currently testing this drug in a Phase 1 study in subjects with hematologic malignancies. KaloBios plans to begin the phase 2 portion of this study in AML and MDS before the end of 2013.
  • All of the company's antibodies were generated using its proprietary Humaneered® technology, a method that converts nonhuman antibodies (typically mouse) into recombinant antibodies that have a high binding affinity to their target and are designed for chronic therapeutic use. The company believes that antibodies produced using its Humaneered® technology offer important clinical and economic advantages over antibodies generated by other methods in terms of high binding affinity, high manufacturing yields, and minimal to no immunogenicity (inappropriate immune response) upon repeat administration in humans.

    For more information on KaloBios Pharmaceuticals, please visit our web site at http://www.kalobios.com.

    Forward Looking Statements

    This release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including: the statements under the heading "Anticipated Upcoming Milestones for 2013-2014"; and statements regarding the company's clinical development of
    '/>"/>

    SOURCE KaloBios Pharmaceuticals, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5

    Related biology news :

    1. Cell therapy using patients own bone marrow may present option for heart disease
    2. Report presents designs for study of cancer risks near US nuclear facilities
    3. Entomology 2012 to present 105 insect symposia in November
    4. NYU School of Medicine presents 2012 Dart/NYU Biotechnology Achievement Awards
    5. The Brain Prize 2012 is presented May 9th
    6. Validity CTO to Present Natural ID Solutions for Improving Mobile Risk Management and User Experience at NFC Solutions Summit 2012
    7. John Theurer Cancer Center presents significant blood cancer research at 2012 ASCO Annual Meeting
    8. Amarantus BioSciences to Present at the National Investment Banking Associations (NIBA)122nd Conference in New York City
    9. Coral reef experts to present latest coral reef science during July symposium
    10. FirstMark Exhibiting and Presenting at the San Diego Academy of Family Physicians 55th Annual Postgraduate Symposium
    11. GSA Bulletin presents studies in Antarctica, Italy, Mexico, Algeria, Mongolia, and more
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/17/2014)... social behavior by studying nonhuman mammals and primates, but ... their unusually large brains relative to their body size ... environment---not merely in a large population of cooperating creatures, ... setting of alliances and competitors. The same is true ... social carnivores, like hyenas and lions. , A new ...
    (Date:9/16/2014)... women in Australia is increased by lower socioeconomic ... September) in BJOG: An International Journal of ... high standards of living; however, existing research has ... indigenous and non indigenous Australians. , This case-control ... socioeconomic position on severe maternal morbidities associated with ...
    (Date:9/16/2014)... "molecular brakes" that time the generation of important cells ... cells" translate sound waves into electrical signals that are ... If the arrangement of the cells is disordered, hearing ... will be published in The Journal of Neuroscience ... Hey2 act as brakes to prevent hair cell generation ...
    Breaking Biology News(10 mins):Being social: Learning from the behavior of birds 2New study examines the impact of socioeconomic position & maternal morbidity in Australia 2New study examines the impact of socioeconomic position & maternal morbidity in Australia 3Hey1 and Hey2 ensure inner ear 'hair cells' are made at the right time, in the right place 2
    ... Journal of Animal Science , meat scientists report that ... at the USDA-ARS, Roman L. Hruska US Meat Animal Research ... muscle (LM) tenderness and other meat quality traits between different ... The pigs used in this study came from one ...
    ... Researchers from North Carolina State University have developed a ... approaches and can be used to create technologies with ... lithography can be used to manufacture chips for use ... as proteins or genetic material associated with specific medical ...
    ... top wheat experts today reported a breakthrough in their ability ... rapidly mutating wheat pathogen called stem rust that threatens wheat ... by farmers and scientists from fields and laboratories, the creators ... 42 million hectares of wheat in 27 developing countries in ...
    Cached Biology News:Chilling methods could change meat tenderness 2Researchers develop new, less expensive nanolithography technique 2Researchers launch new 'Rust-Tracker' to monitor deadly wheat fungus in 27 nations 2Researchers launch new 'Rust-Tracker' to monitor deadly wheat fungus in 27 nations 3Researchers launch new 'Rust-Tracker' to monitor deadly wheat fungus in 27 nations 4Researchers launch new 'Rust-Tracker' to monitor deadly wheat fungus in 27 nations 5Researchers launch new 'Rust-Tracker' to monitor deadly wheat fungus in 27 nations 6
    (Date:9/17/2014)... WA , Sept. 17, 2014 /PRNewswire/ - Oncothyreon ... it intends to offer and sell shares of its ... separate but concurrent underwritten public offerings.  The Series A ... of Oncothyreon Common Stock, provided that conversion will be ... affiliates would beneficially own more than 4.99% of the ...
    (Date:9/17/2014)... A biodegradable polymer can be ... bacteria, fungi, and algae into smaller units (monomers) ... compounds, carbon dioxide, and humus in a specified ... improved costs, biodegradable polymers are proving to be ... conventional polymers. Primary factors that are responsible for ...
    (Date:9/17/2014)... Intarcia Therapeutics, Inc. today announced the presentation ... cost and predictability of non-adherence in type 2 diabetes ... the European Association for the Study of Diabetes (EASD). ... Ph.D., of Analysis Group, Inc. presented data from the ... to characterize the prevalence of non-adherence and serial non-adherence, ...
    (Date:9/17/2014)... , Sept. 17, 2014 RXi ... biotechnology company focused on discovering, developing and commercializing ... RNA-targeted technologies, today announced that it has been granted ... Trademark Office on its unique delivery system for ... to phagocytic cells for the treatment of diseases ...
    Breaking Biology Technology:Oncothyreon Announces Proposed Public Offerings 2Growing Demand for Eco-Friendly Products Drives the Global Biodegradable Polymers Market, According to New Report by Global Industry Analysts, Inc. 2Growing Demand for Eco-Friendly Products Drives the Global Biodegradable Polymers Market, According to New Report by Global Industry Analysts, Inc. 3Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 2Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 3Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 4Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 5RXi Pharmaceuticals Strengthens Intellectual Property Portfolio 2RXi Pharmaceuticals Strengthens Intellectual Property Portfolio 3RXi Pharmaceuticals Strengthens Intellectual Property Portfolio 4
    ... , , ... , ... for culturing cells in a BioFlo ,110 benchtop fermentor/bioreactor system. ... and control modules to,enable growth of a wide variety of cultures, ...
    ... Microscale on-membrane PMF analysis can be ... function of a chemical printer (Refer to AXIMA Application 14, 17). ... chemical printer enables MS analysis with high mass accuracy ( , ... separated by 2-dimensional electrophoresis were transferred to a PVDF membrane for ...
    ... Achieving Ultra Fast Liquid Chromatography ... , Prominence UFLC has ... this respect, we are successful,in demonstrating high speed and separation performance,without ... with other fast,LC systems., Smaller ...
    Cached Biology Technology:CHO Cell Culture Application Using a BioFlo 110 Benchtop Bioreactor 2CHO Cell Culture Application Using a BioFlo 110 Benchtop Bioreactor 3CHO Cell Culture Application Using a BioFlo 110 Benchtop Bioreactor 4Direct On-Membrane MS/MS Analysis using the Chemical Printer (CHIP-1000) and AXIMA-QIT 2Prominence UFLC 2Prominence UFLC 3Prominence UFLC 4Prominence UFLC 5Prominence UFLC 6Prominence UFLC 7Prominence UFLC 8
    ... for biological safety labs (BSL) and ... Class 10/ISO 3) and easy sterilization. ... surfaces that are easy to wipe ... simplify cleaning. Unique double-wall panel design ...
    ... cleanroom for biological safety labs (BSL) ... (to Class 10/ISO 3) and easy ... ultra-smooth surfaces that are easy to ... corners simplify cleaning. Unique double-wall panel ...
    Sigmas E-TOXATE (Limulus Amebocyte Lysate) test kits are intended for the detection and semiquantitation of endotoxins for research purposes. sensitivity 0.05-0.1 EU/mL...
    ... testing at various temperatures, this chamber ... a clean heating unit to maintain ... 140F. Transparent panels allow full visibility, ... access to the work area. Includes ...
    Biology Products: